Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05166421 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 224
- Enrollment target
NCT05166421 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 224 participants.
The verdict
NCT05166421, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 224 participants
- Enrollment target
Study Summary
The study will assess pharmacokinetic (PK) comparability between different formulations of AZD7442, which is a combination of two individual monoclonal antibodies (mAbs), AZD8895 and AZD1061.
Interventions
- BIOLOGICAL AZD7442
- BIOLOGICAL AZD8895 (clonal cell line material)
- BIOLOGICAL AZD1061 (clonal cell line material)
- BIOLOGICAL AZD8895 (cell pool material)
- BIOLOGICAL AZD1061 (cell pool material)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2023-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05166421
The ClinicalTrials.gov registry entry for NCT05166421 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which AZD7442 is the first listed.
NCT05166421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05166421 about?
NCT05166421 is a clinical study titled "Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants". The study will assess pharmacokinetic (PK) comparability between different formulations of AZD7442, which is a combination of two individual monoclonal antibodies (mAbs), AZD8895 and AZD1061.
What is the current status of trial NCT05166421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 224 participants. The study started on 2021-11-30. Estimated completion is 2023-07-19.
What interventions are being tested in trial NCT05166421?
The interventions under investigation include: AZD7442 (BIOLOGICAL), AZD8895 (clonal cell line material) (BIOLOGICAL), AZD1061 (clonal cell line material) (BIOLOGICAL), AZD8895 (cell pool material) (BIOLOGICAL), AZD1061 (cell pool material) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05166421?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.